Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04841577
Registration number
NCT04841577
Ethics application status
Date submitted
8/04/2021
Date registered
12/04/2021
Date last updated
18/10/2022
Titles & IDs
Public title
A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 60 Years and Above
Query!
Scientific title
A Phase 3, Open-label, Randomized, Controlled, Multi-country Study to Evaluate the Immune Response, Safety and Reactogenicity of RSVPreF3 OA Investigational Vaccine When Co-administered With FLU-QIV Vaccine in Adults Aged 60 Years and Above
Query!
Secondary ID [1]
0
0
214488
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Respiratory Syncytial Virus Infections
0
0
Query!
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Other respiratory disorders / diseases
Query!
Infection
0
0
0
0
Query!
Other infectious diseases
Query!
Infection
0
0
0
0
Query!
Studies of infection and infectious agents
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - RSVPreF3 OA investigational vaccine
Other interventions - FLU-QIV
Experimental: Co-Ad Group - Participants received 1 dose of RSV_PreF3 Older Adult (OA) investigational vaccine and 1 dose of FLU-QIV at Day 1 and were followed up until the study end.
Active Comparator: Control Group - Participants received 1 dose of FLU-QIV at Day 1 and 1 dose of RSV_PreF3 OA investigational vaccine at Day 31 and were followed up until the study end.
Other interventions: RSVPreF3 OA investigational vaccine
RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm.
Other interventions: FLU-QIV
FLU-QIV administered intramuscularly in the deltoid region of the dominant (Co-Ad Group) arm or the non-dominant (Control Group) arm.
Query!
Intervention code [1]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
RSV-A Neutralization Antibody Titers Expressed as Geometric Mean Titers (GMTs)
Query!
Assessment method [1]
0
0
The serum neutralization assay is a functional assay that measures the ability of serum antibodies to neutralize RSV-A entry and replication in a host cell line. The serum neutralizing antibody titer is expressed in ED60 (Estimated Dilution 60) and corresponds to the inverse of the interpolated serum dilution that yields a 60% reduction of the signal compared to a control without serum.
Query!
Timepoint [1]
0
0
At 1 month after the RSV_PreF3 OA investigational vaccine dose (at Day 31 for the Co-Ad Group and at Day 61 for the Control Group)
Query!
Primary outcome [2]
0
0
Hemagglutinin Inhibition (HI) Antibody Titers for Each of the FLU Vaccine Strains Expressed as Group GMTs
Query!
Assessment method [2]
0
0
HI antibody titers were assessed for each of the Flu vaccine strains, namely Flu A/Hong Kong/2671/2019 (H3N2), Flu A/Victoria/2570/2019 (H1N1), Flu B/Phuket/3073/2013 (Yamagata) and Flu B/Washington/02/2019 (Victoria). The serum HI antibody titers are expressed in 1/Dilution (DIL) where DIL corresponds to the highest dilution that shows complete HI.
Query!
Timepoint [2]
0
0
1 month after the FLU vaccine dose (at Day 31)
Query!
Secondary outcome [1]
0
0
Secondary: HI Seroconversion Status for Each of the Flu Vaccine Strains Expressed as Seroconversion Rate (SCR)
Query!
Assessment method [1]
0
0
SCR for HI antibody response was defined as the percentage of vaccinees who have either a HI pre-dose titer < 1:10 and a post-dose titer >= 1:40 or a pre-dose titer >= 1:10 and at least a four-fold increase in post-dose titer. HI antibody titers were assessed for each of the Flu vaccine strains, namely Flu A/Hong Kong/2671/2019 (H3N2), Flu A/Victoria/2570/2019 (H1N1), Flu B/Phuket/3073/2013 (Yamagata) and Flu B/Washington/02/2019 (Victoria).
Query!
Timepoint [1]
0
0
1 month after the FLU vaccine dose (at Day 31)
Query!
Secondary outcome [2]
0
0
RSV-A Neutralization Antibody Titers Expressed as Mean Geometric Increase (MGI)
Query!
Assessment method [2]
0
0
MGI was defined as the geometric mean of the within participant ratios of the post dose titer over the pre-dose titer.
Query!
Timepoint [2]
0
0
1 month after the RSV_PreF3 OA investigational vaccine dose (at Day 31 for the Co-Ad Group and at Day 61 for the Control Group)
Query!
Secondary outcome [3]
0
0
RSV-B Neutralization Antibody Titers Expressed as Geometric Mean Titers (GMT)
Query!
Assessment method [3]
0
0
The serum neutralization assay is a functional assay that measures the ability of serum antibodies to neutralize RSV-B entry and replication in a host cell line. The serum neutralizing antibody titer is expressed in ED60 (Estimated Dilution 60) and corresponds to the inverse of the interpolated serum dilution that yields a 60% reduction of the signal compared to a control without serum.
Query!
Timepoint [3]
0
0
1 month after the RSV_PreF3 OA investigational vaccine dose (at Day 31 for the Co-Ad Group and at Day 61 for the Control Group)
Query!
Secondary outcome [4]
0
0
RSV-B Neutralization Antibody Titers Expressed as MGI
Query!
Assessment method [4]
0
0
MGI was defined as the geometric mean of the within participant ratios of the post-dose titer over the pre-dose titer.
Query!
Timepoint [4]
0
0
1 month after the RSV_PreF3 OA investigational vaccine dose (at Day 31 for the Co-Ad Group and at Day 61 for the Control Group)
Query!
Secondary outcome [5]
0
0
HI Antibody Titers for Each of the FLU Vaccine Strains Expressed as GMTs
Query!
Assessment method [5]
0
0
HI antibody titers were assessed for each of the Flu vaccine strains, namely A/Hong Kong/2671/2019 (H3N2), Flu A/Victoria/2570/2019 (H1N1), Flu B/Phuket/3073/2013 (Yamagata) and Flu B/Washington/02/2019 (Victoria). The serum HI antibody titers are expressed in 1/DIL where DIL corresponds to the highest dilution that shows complete HI.
Query!
Timepoint [5]
0
0
At baseline (at Day 1) and 1 month after the FLU vaccine dose (at Day 31)
Query!
Secondary outcome [6]
0
0
HI Seroprotection Status for Each of the FLU Vaccine Strains Expressed as Seroprotection Rate (SPR)
Query!
Assessment method [6]
0
0
SPR for HI antibody response was defined as percentage of vaccinees with a serum HI titer >= 1:40 that usually is accepted as indicating protection. HI antibody titers were assessed for each of the Flu vaccine strains, namely A/Hong Kong/2671/2019 (H3N2), Flu A/Victoria/2570/2019 (H1N1), Flu B/Phuket/3073/2013 (Yamagata) and Flu B/Washington/02/2019 (Victoria).
Query!
Timepoint [6]
0
0
At baseline (at Day 1) and 1 month after the FLU vaccine dose (at Day 31)
Query!
Secondary outcome [7]
0
0
HI Antibody Titers for Each of the FLU Vaccine Strains Expressed as MGI
Query!
Assessment method [7]
0
0
MGI was defined as the geometric mean of the within participant ratios of the post-dose titer over the pre-dose titer. HI antibody were assessed for each of the FLUvaccine strain, namely A/Hong Kong/2671/2019 (H3N2), Flu A/Victoria/2570/2019 (H1N1), Flu B/Phuket/3073/2013 (Yamagata) and Flu B/Washington/02/2019 (Victoria).
Query!
Timepoint [7]
0
0
1 month after the FLU vaccine dose (at Day 31)
Query!
Secondary outcome [8]
0
0
Percentage of Participants With Solicited Administration Site Events
Query!
Assessment method [8]
0
0
Solicited administration site adverse events(AEs) assessed were erythema, pain and swelling. Any = occurrence of the adverse event regardless of intensity grade.
Query!
Timepoint [8]
0
0
Within 4 days (the day of vaccination and 3 subsequent days) after each vaccination
Query!
Secondary outcome [9]
0
0
Percentage of Participants With Solicited Systemic Events
Query!
Assessment method [9]
0
0
Solicited systemic events assessed were arthralgia, fatigue, fever [defined as temperature equal to or above (>=) 38 degrees Celsius (C)/100.4 degrees Fahrenheit (F)], headache and myalgia. Any = occurrence of the adverse event regardless of intensity grade or relation to study vaccination.
Query!
Timepoint [9]
0
0
Within 4 days (the day of vaccination and 3 subsequent days) after each vaccination
Query!
Secondary outcome [10]
0
0
Percentage of Participants Reporting at Least One Unsolicited Adverse Event
Query!
Assessment method [10]
0
0
An unsolicited AEs is any AE reported in addition to those solicited during the clinical study and that was not included in a list of solicited events using a Participant Diary. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited adverse event. Unsolicited AEs include serious, non-serious AEs and potential immune-mediated diseases (pIMDs). Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
Query!
Timepoint [10]
0
0
Within 30 days (the day of vaccination and 29 subsequent days) after each vaccination
Query!
Secondary outcome [11]
0
0
Percentage of Participants Reporting at Least One Serious Adverse Event (SAE)
Query!
Assessment method [11]
0
0
An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant. Any = occurrence of the symptom regardless of intensity grade or relationship to vaccination.
Query!
Timepoint [11]
0
0
From Day 1 up to study end (6 months after last vaccination)
Query!
Secondary outcome [12]
0
0
Percentage of Participants Reporting at Least One Potential Immune-mediated Disease (pIMD)
Query!
Assessment method [12]
0
0
pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.
Query!
Timepoint [12]
0
0
From Day 1 up to study end (6 months after last vaccination)
Query!
Eligibility
Key inclusion criteria
- Participants, who, in the opinion of the investigator, can and will comply with the
requirements of the protocol A male or female =60 YOA at the time of the first study
intervention administration.
- Participants living in the general community or in an assisted-living facility that
provides minimal assistance, such that the participant is primarily responsible for
self-care and activities of daily living.
- Written or witnessed informed consent obtained from the participant prior to
performance of any study-specific procedure.
- Participants who are medically stable in the opinion of the investigator at the time
of first vaccination. Participants with chronic stable medical conditions with or
without specific treatment are allowed to participate in this study if considered by
the investigator as medically stable.
Query!
Minimum age
60
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
Medical conditions
- Any confirmed or suspected immunosuppressive or immunodeficient condition resulting
from disease or immunosuppressive/cytotoxic therapy based on medical history and
physical examination.
- History of any reaction or hypersensitivity likely to be exacerbated by any component
of the vaccines.
- Hypersensitivity to latex.
- History of GBS, anaphylaxis, febrile seizures, Bell's palsy and narcolepsy.
- Serious or unstable chronic illness.
- Any history of dementia or any medical condition that moderately or severely impairs
cognition.
- Recurrent or un-controlled neurological disorders or seizures. Participants with
medically-controlled active or chronic neurological diseases can be enrolled in the
study as per investigator assessment, provided that their condition will allow them to
comply with the requirements of the protocol (e.g. completion of diary cards, attend
regular phone calls/study site visits).
- Significant underlying illness that in the opinion of the investigator would be
expected to prevent completion of the study
- Any medical condition that in the judgment of the investigator would make
intramuscular injection unsafe.
Prior/Concomitant therapy
- Use of any investigational or non-registered product (drug, vaccine or medical device)
other than the study interventions during the period beginning 30 days before the
first dose of study vaccines and ending 30 days after the last vaccine administration,
or planned use during the study period.
- Administration of an influenza vaccine during the 6 months preceding the study FLU-QIV
administration.
- Planned or actual administration of a vaccine not foreseen by the study protocol in
the period starting 30 days before the first study intervention administration and
ending 30 days after the last study intervention administration.
Note: In case an emergency mass vaccination for an unforeseen public health threat is
recommended and/or organized by the public health authorities, outside the routine
immunization program, the time period described above can be reduced if necessary for that
vaccine provided it is used according to the local governmental recommendations and that
the Sponsor is notified accordingly.
- Previous vaccination with an RSV vaccine.
- Administration of long-acting immune-modifying drugs or planned administration at any
time during the study period).
- Administration of immunoglobulins and/or any blood products or plasma derivatives
during the period starting 90 days before the first dose of study vaccine or planned
administration during the study period.
- Chronic administration (defined as more than 14 consecutive days in total) of
immunosuppressants or other immune-modifying drugs during the period starting 90 days
prior to the first study vaccination or planned administration during the study
period. For corticosteroids, this will mean prednisone =20 mg/day, or equivalent.
Inhaled and topical steroids are allowed.
Prior/Concurrent clinical study experience
• Concurrently participating in another clinical study, at any time during the study
period, in which the participant has been or will be exposed to an investigational or a
non-investigational intervention (drug/invasive medical device).
Other exclusions
- History of chronic alcohol consumption and/or drug abuse as deemed by the investigator
to render the potential participant unable/unlikely to provide accurate safety reports
or comply with study procedures.
- Planned move during the study conduct that prohibits participation until 1 month
post-last vaccine administration.
- Bedridden participants.
- Participation of any study personnel or their immediate dependents, family, or
household members.
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
27/04/2021
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
8/02/2022
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
976
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
New Zealand
Query!
State/province [1]
0
0
Auckland
Query!
Country [2]
0
0
New Zealand
Query!
State/province [2]
0
0
Christchurch
Query!
Country [3]
0
0
New Zealand
Query!
State/province [3]
0
0
Havelock North
Query!
Country [4]
0
0
New Zealand
Query!
State/province [4]
0
0
Paraparaumu
Query!
Country [5]
0
0
New Zealand
Query!
State/province [5]
0
0
Tauranga
Query!
Country [6]
0
0
New Zealand
Query!
State/province [6]
0
0
Wellington
Query!
Country [7]
0
0
Panama
Query!
State/province [7]
0
0
Ciudad de Panama
Query!
Country [8]
0
0
Panama
Query!
State/province [8]
0
0
Panama
Query!
Country [9]
0
0
South Africa
Query!
State/province [9]
0
0
Gauteng
Query!
Country [10]
0
0
South Africa
Query!
State/province [10]
0
0
Mpumalanga
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
GlaxoSmithKline
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to assess the immunogenicity, safety and reactogenicity of the
RSVPreF3 OA investigational vaccine when co-administered with the seasonal quadrivalent
influenza vaccine (FLU-QIV) in adults aged 60 years and above compared to separate
administration of the vaccines.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04841577
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04841577
Download to PDF